Mazdutide

Mazdutide is a long-acting, once-weekly, injectable medicine that is under development for obesity and type 2 diabetes. It is currently undergoing phase 3 clinical trials and is not expected to be submitted for FDA approval until pre-marketing clinical trials have finished, and results have continued to be favorable.

How does mazdutide work?

Mazdutide is a dual glucagon-like peptide 1 receptor agonist (GLP-1RA) and glucagon receptor agonist, the first in its class. By activating both GLP1R and glucagon receptors it helps regulate appetite, metabolism, and improve glucose control. This dual effect appears promising but more clinical trials are needed.